RFA-HL-23-005: NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
Closed
This grant is closed. A newer notice from the same program is open now: NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) (RFA-HL-26-003). Status: Closes April 28, 2027 (172 days left). It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $700,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 20 awards worth $20.0 million in total. Applications closed on April 25, 2024.
From the official notice on Grants.gov, last changed May 5, 2021. Checked November 7, 2026.
- Award ceiling$700,000
- Total funding$20.0 million
- Expected awards20
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR35
- Clinical trialsOptional
- Funded byNHLBI
- Median yearly award$873,329
- Typical project length7 years
- R35, Outstanding Investigator Award. Support for an investigator's whole research program rather than a single project (this includes MIRA awards). Other open R35 notices.
Projects funded under RFA-HL-23-005 were run by National Heart Lung and Blood Institute (NHLBI, 10 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-23-005 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-HL-26-003 | April 26, 2024 | Closes April 28, 2027 (172 days left) | Open |
Key dates
| Posted | May 5, 2021 |
|---|---|
| Deadline | April 25, 2024 |
| Archived by Grants.gov | May 31, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $873,329; it allows up to $700,000 per award.
- Most of the money in the 3 programs behind this notice (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Funded under RFA-HL-23-005 so far
NIH funded 10 projects under RFA-HL-23-005 in fiscal 2023 to 2026, at 10 institutions. The median yearly award was $873,329.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Deciphering how 3D genome organization orchestrates cardiac cellular identity | University of Pennsylvania | 2026 | $866,687 |
| Establishing lifelong trajectories of pulmonary health | University of Rochester | 2026 | $844,477 |
| Epigenetic regulation in cardiac development | Texas A&m University Health Science Ctr | 2026 | $935,316 |
| Genetic and Molecular Mechanisms of Heart Disease | University of Iowa | 2026 | $1.1 million |
| Finding and pushing the limits of macrophage efferocytosis in atherosclerosis | Columbia University Health Sciences | 2026 | $656,633 |
| Cellular and Molecular Control of Normal and Disordered Erythropoiesis | Feinstein Institute for Medical Research | 2026 | $853,132 |
| The epigenetic regulation of inflammation in tissue repair and vascular disease | University of Michigan at Ann Arbor | 2026 | $1.0 million |
| Sex-specific factors, inflammation and vascular health across the lifespan in women living with HIV | Johns Hopkins University | 2026 | $484,874 |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Lung Diseases Research grants before
From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 1 | $5.4 million |
| New England Research Institutes Inc | Massachusetts | 1 | $2.7 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 1 | $355,699 |
| University of Washington | Washington | 1 | $350,272 |
| The Trustees of Columbia University in the City of New York | New York | 1 | $319,659 |
Who has won Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders grants before
From fiscal 2021 to 2025, Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (93.840) awarded $3.3 million across 9 grant awards, an average of $364,164 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of Colorado | Colorado | 1 | $1.5 million |
| Indiana Department of Health | Indiana | 1 | $558,986 |
| Minnesota Department of Health | Minnesota | 1 | $442,754 |
| Michigan Public Health Institute | Michigan | 1 | $311,837 |
| City of Philadelphia | Pennsylvania | 1 | $251,231 |
Applying now
This notice no longer takes applications. Apply under the newer notice, RFA-HL-26-003, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HL-23-005 still open?
No. It closed on April 25, 2024. A newer notice is open: RFA-HL-26-003, closes April 28, 2027 (172 days left).
Who can apply for NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)?
Closed April 25, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $700,000 each. About $20.0 million in total across about 20 awards.
Who has been funded under RFA-HL-23-005?
NIH RePORTER lists 10 projects funded under RFA-HL-23-005 in fiscal 2023 to 2026, at 10 institutions. The most were at University of Pennsylvania, University of Rochester, Texas A&m University Health Science Ctr.
Who has won Cardiovascular Diseases Research grants before?
The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.
Similar open grants
- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Investigator-Focused Award (Parent R35)
- Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)